Program Announcement for the Defense Health Agency

Orthopaedic Research Program Applied Research Award

Funding Opportunity Number: HT942526ORPARA

Pre-Application Due: August 19, 2026

Application Due: November 18, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click ⓘ to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The Orthopaedic Research Program (ORP) Applied Research Award (ARA) seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities.

Distinctive Features:

- **Applied research** is defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies.
- **Preliminary** data is required.
- **Military relevance**: the ORP expects that research findings benefit Service Members, their families, Veterans and the general public.
- Clinical research is not allowed unless exempt under Title 32, Code of Federal Regulations, Part 219, Section 104(d) (32 CFR 219.104[d]) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
- Clinical trials are **not** allowed.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $3.8M to fund approximately four ARA applications with total cost caps of $950,000 per award. The maximum period of performance is 3 years. It is anticipated that awards made from this fiscal year 2026 (FY26) funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), August 19, 2026
- **Invitation to Submit an Application:** September 25, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, November 18, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, November 23, 2026
- **Peer Review:** January 2027
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526ORPARA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators at all career levels affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status.

There is no limitation on the number of applications for which an investigator may be named PI.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Orthopaedic Research Program (ORP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the ORP in 2009 to provide support for research of high potential impact and exceptional scientific merit focused on optimizing recovery and restoration of function for military personnel with orthopaedic injuries sustained in combat or service-related duties. Appropriations for the ORP from FY09 through FY24 totaled $548.5 million (M). The FY26 appropriation is $20M.

The FY26 ORP challenges the scientific community to address the most significant gaps in care for the leading burden of injury and for facilitating return to duty. The program intends to support high-impact and clinically relevant research to advance treatment and rehabilitation from orthopaedic injuries (excluding spinal cord injuries) sustained during combat and service-related activities to maximize return to duty. It is expected that research findings would also benefit the general population. Applications involving interdisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA) and/or other federal agencies are highly encouraged.

FY26 congressional language for the Arthritis Research Program directed that arthritis research shall not be considered by other CDMRP peer reviewed programs such as ORP. The FY26 ORP will consider research that addresses conditions or health abnormalities related to arthritis.

3.1. Award History

The ORP Applied Research Award (ARA) mechanism was first offered in FY15. Since then, 485 ARA applications were received, and 81 were recommended for funding.

3.2. Intent of the Applied Research Award

The FY26 ORP ARA seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat and service-related activities. The ORP encourages applicants to address how the proposed research will support patient care and allow patients to more quickly return to duty/work. The program expects that any research findings will also provide benefit to the general population.

The FY26 ORP ARA focuses on **applied research**, defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies.

Research proposed under the FY26 ORP ARA may include small- to large-scale projects.

Studies allowed under the FY26 ORP ARA may include, but are not limited to:

- Evaluation, maturation and/or down-selection of potential product candidates (drugs, biologic constructs or devices/systems) in vitro and/or in vivo.

- Preparation activities needed to support a future clinical trial or regulatory submission.

Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.

3.2.1. Focus Areas for the ARA

Applications submitted to the FY26 ORP ARA must address one or more of the following focus areas:

- **Battlefield Fracture-Related Infection:** Strategies to decrease the burden of fracture-related infections on the battlefield, which may include prevention, early detection or improved eradication. The ORP encourages applications proposing alternatives to systemic antibiotic delivery. The ORP will not consider applications proposing strategies not feasible in a battlefield or combat environment.
- **Composite Tissue Regeneration:** Advanced tissue regeneration therapeutics in composite tissue for the restoration of traumatically injured extremities. The ORP encourages applications proposing techniques aimed at improving outcomes following high-energy extremity trauma, with a focus on improving wound healing and neuromuscular recovery following composite tissue loss and segmental bone loss. The ORP will not consider tissue engineering studies that solely address bone, cartilage, muscle or nerve.
- **Limb Stabilization and Protection**: Development and/or clinical evaluation of rapid limb stabilization and novel wound protectants for severely or critically wounded limbs to enable prolonged care and eventual transport to the point of definitive treatment. The ORP will not consider applications proposing interventions that solely address infection.
- **Osteointegration Outcomes:** Identification of best practices to optimize outcomes of patients who have percutaneous osseointegrated prosthetic limbs, e.g., infection, rejection, adapters and fail-safe devices, clinical outcomes.
- **Return-to-Duty Strategies:** Optimization and/or validation of decision-support tools, interventions and/or rehabilitation strategies that can retain a Service Member on duty, enable them to return to duty within one year of injury or avoid reinjury for common combat-related musculoskeletal injuries. Applications must describe the current standard of care and the proposed rehabilitation strategy, as applicable. The ORP encourages applications proposing treatment strategies for use along the continuum of care, capabilities for diagnosis of underlying pathology and efficacy of intervention measurements. The ORP will not consider applications proposing biomarker studies.

3.2.2. Key Elements for the ARA

- **Impact:** Upon successful completion, the proposed research is expected to yield knowledge products, approaches or technologies that have the potential to advance toward clinical translation. Strong transition plans are expected.
- **Preliminary Data:** Applications must include preliminary and/or published data relevant to the proposed research and demonstrate logical reasoning for the proposed work. To be competitive, the application must include a sound scientific rationale and a well-formulated, testable hypothesis established through a critical review and analysis of literature.

- **Military Benefit:** Research outcomes must benefit Service Members, their families and Veterans, as well as the general public. PIs are encouraged to integrate and/or align their research projects with DOW and/or VA research laboratories and programs. Collaboration with the DOW and/or VA is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOW and VA areas of research interest or potential opportunities for collaboration can be found in Appendix 10 of the GAI.

3.2.3. Other Important Considerations for the Applied Research Award

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Applications to the FY26 ORP ARA mechanism **must** support preclinical applied research**.**

Clinical research *studies are not allowed within this funding opportunity* ***unless exempt under 32 CFR 219.104[d] or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.***

Clinical trials are not allowed within this funding opportunity.

Applicants seeking support for clinical trials and/or clinical research projects should consider the FY26 ORP Clinical Research Award (Funding Opportunity Number HT942526ORPCRA) mechanism.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the VA and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **3** years.

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$950,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

Must be requested for:

- Travel costs for the PI to present project information or disseminate project results at one DOW-sponsored meetings (e.g., the Military Health System Research Symposium) during Year 3 of the project's period of performance. For planning purposes, it should be assumed that the meeting will be held in the National Capital or Central Florida areas. These travel costs are in addition to those allowed for annual scientific/technical meetings.

Must not be requested for:

- Clinical trial costs.
- Clinical research costs unless exempt under 32 CFR 219.104[d] or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

- **Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - **Background/Research Problem/Rationale:** Describe the research problem to be addressed by the proposed study and the rationale on which it is based. State how the proposed research addresses the intent of the award mechanism.
  - **Objective/Hypothesis:** State the objective(s) to be reached and/or hypothesis to be tested.
  - **Specific Aims and Study Design:** Concisely state the specific aims of the study and describe the scientific approach and how it will accomplish the study aims. Include a description of controls, as appropriate.
  - **Impact:** State the FY26 ORP ARA Focus Area(s) addressed by the proposed research. Briefly describe how the proposed project will have an impact on patient care for those who have sustained traumatic orthopaedic injuries, service-related or otherwise.
- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application ***must be uploaded as individual files*** and are limited to the following:
  - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
  - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols used in the Preproposal Narrative.

- **Key Personnel Biographical Sketches: *All biographical sketches should be uploaded as a single combined file.*** Biographical sketches should be used to demonstrate background and expertise through education, positions, publications and previous work accomplished.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (12-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below.

  - **Background:** Establish the relevance of the study to an FY26 ORP ARA Focus Area. Describe in detail the rationale for the study questions and/or study hypotheses. Cite relevant literature. Include preliminary data that led to the development of the proposed project. State how the proposed work is a refinement or maturation of any existing work or research.
  - **Objectives/Specific Aims/Hypotheses:** State the hypotheses to be tested or the objectives to be reached. Concisely explain the specific aims of the proposed project.
  - **Research Strategy and Feasibility:**
    - Describe the study design, methods and models, including appropriate controls, in sufficient detail for evaluation of appropriateness and feasibility.
    - Explain how this research strategy will meet the research goals and milestones.
    - Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.
    - Provide a well-developed, well-integrated and detailed research plan that supports the translational feasibility and promise of the approach.
    - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handles, and identification of primary endpoints.
    - If proposing development of a drug or device, describe how the study design and data reporting would support a regulatory filing with the U.S. Food and Drug Administration (FDA) or international equivalent, if applicable.

- If the proposed research involves access to military and/or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the General Application Instructions, Appendix 4, for additional considerations.

– **Technical Risks:** Identify and describe potential problem areas in the proposed approach and alternative methods and approaches that will be employed to mitigate any risks that are identified. Provide evidence to support availability of and access to the animal model or human samples required for the study, as applicable.

– **Statistical and Data Analysis Plan:** Describe the statistical model and data analysis plan with respect to the study objectives as appropriate to the type of study. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study.

- If any biological material will be used in the proposed studies, the name, definition, pathological classification and source of the material must be provided.
- If human anatomical samples will be used, include a detailed plan for the acquisition of samples.

○ **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

– **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

– **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.

– **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

– **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

– **Letters of Support (one-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations,

databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

- **Letters of Commitment (*if applicable*) (one-page limit per letter is recommended**): If the proposed study involves use of an investigational drug, device or biologic, provide a letter of commitment from the entity that holds the intellectual property rights indicating availability of the product for the duration of the study, support for the proposed phase of research and support for the indication to be tested.
- **Sex as a Biological Variable Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.
- **Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost or other considerations). The plan should also protect participant privacy, confidential and proprietary data and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

  Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management attachment.

  Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** State the FY26 ORP ARA Focus Area(s) addressed by the proposed research. State how the proposed research addresses the intent of the award mechanism. Present the scientific rationale behind the proposed research project.

- **Objective(s)/Hypothesis:** State the hypothesis to be tested and/or objective(s) to be reached. Provide evidence or rationale that supports the objective/hypothesis.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Impact and Military Benefit:** State explicitly how the proposed work may have a short- and/or long-term impact on patient care and/or restoration of function for those who have sustained traumatic orthopaedic injuries, combat-related or otherwise.

○ **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- Summarize the objectives and rationale for the proposed research. State the FY26 ORP ARA Focus Area(s) addressed by the proposed research.
- What are the potential applications, benefits and risks of the anticipated outcomes?
- What is the projected time it may take to achieve a clinically relevant outcome? If the research is far from clinical applicability, describe the interim outcomes.
- Describe how the proposed work may have a short- and/or long-term impact on patient care and/or restoration of function for those who have sustained traumatic orthopaedic injuries, combat-related or otherwise.

○ **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to the Example: Assembling a Generic Statement of Work. Include milestones for data or research resource(s) sharing.

○ **Attachment 6: Impact Statement (two-page limit): Upload as "Impact.pdf".**

- Describe the short- and long-term impact of this study in a manner that will be readily understood by readers with and without a background in science or medicine.
- Discuss how the expected results of the proposed work will contribute to the goals of decreasing the clinical impact of traumatic orthopaedic injuries and provide better long-term outcomes for these patients.
- Provide information about the incidence and/or prevalence of the project-relevant orthopaedic injuries in Service Members and/or Veterans, as well as the incidence in the general population, if appropriate and available.
- Identify where along the military (and civilian) pathway of care the proposed product or intervention will be applied. Describe how the proposed study may impact unit readiness, point of injury care, service-associated trauma care and/or allow patients to more quickly return to duty/work.
- If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

○ **Attachment 7: Transition Plan (two-page limit): Upload as "Transition.pdf".**

Describe/discuss the methods and strategies proposed to move the anticipated research outcomes to the next phase of development (e.g., clinical research trials,

commercialization, transition to industry and/or delivery to the civilian or military market) after successful completion of the award. Outline the regulatory strategy, as applicable. Applicants are encouraged to work with their organization's Technology Transfer Office (or equivalent) to develop the transition plan and description of the collaborations and resources that will be used to provide continuity of development. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The plan for post-award transition of the anticipated research outcome should include the components listed below, as appropriate and applicable to the research proposed:

- A brief schedule and milestones for transitioning the anticipated research outcomes to the next phase of development.
- Details of the funding strategy to transition to the next level of development and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for). A description of collaborations and other resources that will be used to provide continuity of development.
- For knowledge products, the description of collaborations and other resources that will provide continuity of development may include proposed development or modification of Clinical Practice Guidelines and recommendations; provider training materials, patient brochures and other clinical support tools; scientific journal publications; models; simulations; and applications.
- The planned indication for the product label, if appropriate, and an outline of the development plan required to support that indication.
- A plan for resolving intellectual and material property issues among participating organizations.
- A description of ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government's ability to access such products or technologies in the future.
- If applicable, address any real or perceived financial conflict of interests (COIs) or biases and briefly state how the COI or bias will be mitigated.

- **Attachment 8: Animal Research Plan (five-page limit): Upload as "AnimalResPlan.pdf".** ***(Attachment 8 is only applicable and required for applications proposing animal studies.)***

  If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

  - Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.
  - Summarize the procedures to be conducted. Describe how the study will be controlled.

- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis and identification of the primary endpoint(s).

○ **Attachment 9: Data Management (two-page limit): Upload as "DataManage.pdf".**

The Data Management attachment should describe all the methods used for data collection and should include the components listed below.

- **Confidentiality:** Address who will have access to study records, data and specimens, including an acknowledgement that representatives of DHACA are eligible to review study records. Address requirements for reporting sensitive information to state or local authorities.
- **Data capture, verification and disposition:** Describe the types of data, software and/or other materials to be produced. Describe how data will be captured and verified. If existing data resources are used, describe the dataset origin. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the standards to be used for data and metadata format and content, and the length of time data will be stored.
- **Data reporting:** Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.
- **Storage:** Describe specimen storage, to include location of storage, how long specimens have been or will be stored, any special conditions required, labeling and disposition. Outline the plan to store specimens for future use, if applicable.
- **Laboratories performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Describe the quality assurance and quality control measures to be used during collection, analysis and processing. If transport of samples is required, describe provisions for ensuring proper storage during transport.

The Data Management attachment should not duplicate the Sharing Plan in Attachment 1: Project Narrative or the NIH Data Management and Sharing plan.

For more guidance on preparing the Data Management attachment, refer to the GAI **DOW Data Management Plan.** While the GAI instructions refer to applications recommended for funding, the specific basic requirements are the same for this attachment.

○ **Attachment 10: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.

○ **Attachment 11: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that

organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Grants.gov	eBRAP.org
i. Research & Related Senior/Key Person Profile (Expanded) ○ **Biographical Sketch** ○ **Current/Pending Support** *Intragovernmental applicants must include their internally supported research and development programs.*	
ii. Research & Related Budget	
iii. Project/Performance Site Location(s)	
iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*	

4.4. Other Application Elements

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526ORPARA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 ORP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 ORP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the ORP, pre-applications will be screened based on the following criteria:

- **Background/Research Problem/Rationale**
  - How well the background and scientific rationale demonstrate sufficient evidence to support the proposed research project.
  - How well the proposed research project addresses the intent of the award mechanism.
- **Objective/Hypothesis**
  - How well the objective(s) and hypothesis have been clearly stated.
- **Specific Aims and Study Design**
  - How well the specific aims are stated and the approach is supported through scientific rationale and referenced literature, and how well the approach will address these aims.
  - How well the controls are described and appropriate to support the study aims.

- **Impact**
  - How well the project addresses an FY26 ORP ARA Focus Area and the intent of the award mechanism.
  - To what extent the potential outcome(s) of the proposed study, if successful, will produce results that are likely to translate into improve patient care for those who have sustained traumatic orthopaedic injuries, service-related or otherwise.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are listed in decreasing order of importance***:***

- **Research Strategy and Feasibility**
  - How well the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the literature, logical reasoning and the presentation of preliminary data or published data.
  - How well the hypotheses or objectives, aims, experimental design, data management plan (if applicable), methods and analyses are developed and support successful completion of the project aims.
  - How well potential problems are acknowledged and alternative approaches are addressed.
  - Whether the application includes sufficient evidence to support availability of and access to the animal model or human samples required for the study, as appropriate.
  - How well the animal study (or studies) is designed to achieve the objectives, including the choice of model and endpoints/outcome measures to be used, if applicable.
  - How well the study (or studies) is designed to achieve reproducible and rigorous results, including controls, sample size estimation, blinding, randomization and data handling.
  - Whether the plan for acquiring the necessary research resources is sufficient for the proposed research project, if applicable.
  - How consistent the methods and procedures are with sound research design.
  - To what degree the statistical plan and power analysis are appropriate for the proposed project and future transition to the next level of development.
  - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong.
- **Impact and Military Benefit**
  - How well the proposed study addresses the selected FY26 ORP ARA Focus Area(s).
  - To what degree the proposed research, if successful, will contribute to the goal of decreasing the clinical impact of traumatic orthopaedic injuries and provide better short- and long-term outcomes for patients.
  - To what extent and how quickly the proposed study, if successful, will impact unit readiness, point of injury care, service-associated trauma care and/or return to duty/work.

- If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

- **Transition Plan**
  - Whether the identified next level of development and/or commercialization is well-described and realistic.
  - If applicable, whether the development plan required to support a new indication for the product label is appropriate.
  - Whether the funding strategy described (e.g., partners, internal/external funding opportunities to be applied for) to bring the anticipated research outcomes to the next level of development is reasonable and realistic.
  - Whether the planned collaborations, schedule and milestones for bringing the study results to the next level of development (e.g., clinical research or trial, transition to industry, delivery to the market) are achievable.
  - How well the application identifies intellectual property ownership, describes an appropriate intellectual and material property plan among all participating organizations (if applicable), and addresses impact of any intellectual property issues on product or technology development and subsequent government access to products or technologies supported by this program announcement.
  - If applicable, whether the mitigation of any real or perceived financial COIs or biases have been addressed.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Personnel**
  - How well the background and expertise of the PI and other key personnel demonstrate their ability to successfully complete the proposed research.
  - How appropriate the composition of the research or study team is to accomplishing the proposed work.
  - How appropriate the expertise and levels of effort are for successful conduct of the proposed work.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 ORP, as evidenced by the following:
    - Adherence to the intent of the funding opportunity
    - Program portfolio composition
    - Programmatic relevance to FY26 ORP ARA Focus Areas
    - Relative impact and military benefit

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section 1, Basic Information about the Funding Opportunity. No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the ORP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing Defense Health Agency (DHA) or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, Institutional Review Board (IRB) or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports and quad charts as well as a final technical progress report and final quad chart will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline whether and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Up to two investigators are expected to present project information and/or results at one DOW-sponsored meeting (e.g., the Military Health System Research Symposium) during the period of performance in Year 3 or 4. For planning purposes, it should be assumed that the meeting will be held in the National Capital Region or Central Florida.

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- Submission of an application for which a letter of invitation was not issued.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 ORP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b)

cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.

- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The PI does not meet the eligibility criteria.
- The invited application proposes a different research project than that described in the pre-application.
- Clinical research not exempt under 32 CFR 219.104[d] or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110 is proposed.
- A clinical trial is proposed.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Impact Statement – Attachment 6, upload as "Impact.pdf"	☐
Transition Plan – Attachment 7, upload as "Transition.pdf"	☐
Animal Research Plan – Attachment 8, upload as "AnimalResPlan.pdf"	☐
Data Management Plan – Attachment 9, upload as "DataManage.pdf"	
Representations ***(Grants.gov submissions only)*** **– Attachment 10, upload as "RequiredReps.pdf"**	☐
Suggested Intragovernmental/Intramural Budget Form ***(if applicable)*** **– Attachment 11, upload as "IGBudget.pdf"**	☐
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) ***(if applicable)***	☐

Appendix 2. Acronym List

ARA	Applied Research Award
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
ORP	Orthopaedic Research Program
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs